Henrik GrÃ©en

List of Publications by Year in descending order

130 papers	2,666 citations	230014 27 h-index	263392 45 g-index
133 all docs	133 docs citations	133 times ranked	4488 citing authors

#	Article	IF	Citations
1	The Quantification of Oxycodone and Its Phase I and II Metabolites in Urine. Journal of Analytical Toxicology, 2022, 46, 55-63.	1.7	2
2	The metabolism of the synthetic cannabinoids ADB‑BUTINACA and ADB‑4en‑PINACA and their detection in forensic toxicology casework and infused papers seized in prisons. Drug Testing and Analysis, 2022, 14, 634-652.	1.6	30
3	Oxycodone-Related Deaths: The Significance of Pharmacokinetic and Pharmacodynamic Drug Interactions. European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47, 259.	0.6	2
4	Postmortem Metabolomics Reveal Acylcarnitines as Potential Biomarkers for Fatal Oxycodone-Related Intoxication. Metabolites, 2022, 12, 109.	1.3	4
5	Characterization of recent non-fentanyl synthetic opioids via three different in vitro µ-opioid receptor activation assays. Archives of Toxicology, 2022, 96, 877-897.	1.9	10
6	The association of four genetic variants with myelosuppression in gemcitabine‑treated Japanese is not evident in gemcitabine/carboplatin‑treated Swedes. Basic and Clinical Pharmacology and Toxicology, 2022, , .	1.2	1
7	The Importance of BHB Testing on the Post-Mortem Diagnosis of Ketoacidosis. Biomolecules, 2022, 12, 9.	1.8	4
8	Structure Elucidation of Urinary Metabolites of Fentanyl and Five Fentanyl Analogs using LC-QTOF-MS, Hepatocyte Incubations and Synthesized Reference Standards. Journal of Analytical Toxicology, 2021, 44, 993-1003.	1.7	12
9	Activation of the µ‑opioid receptor by alicyclic fentanyls: Changes from high potency full agonists to low potency partial agonists with increasing alicyclic substructure. Drug Testing and Analysis, 2021, 13, 169-174.	1.6	7
10	Heroin-Related Compounds and Metabolic Ratios in Postmortem Samples Using LC‑MS-MS. Journal of Analytical Toxicology, 2021, 45, 215-225.	1.7	11
11	High ECG Risk-Scores Predict Late Gadolinium Enhancement on Magnetic Resonance Imaging in HCM in the Young. Pediatric Cardiology, 2021, 42, 492-500.	0.6	10
12	Post-Mortem Metabolomics: A Novel Approach in Clinical Biomarker Discovery and a Potential Tool in Death Investigations. Chemical Research in Toxicology, 2021, 34, 1496-1502.	1.7	11
13	Persistent neuropathy among early-stage breast cancer survivors in a population-based cohort. British Journal of Cancer, 2021, 125, 445-457.	2.9	7
14	Circumstances, Postmortem Findings, Blood Concentrations and Metabolism in a Series of Methoxyacetylfentanyl-Related Deaths. Journal of Analytical Toxicology, 2021, 45, 760-771.	1.7	6
15	A sensitive LC-MS/MS method for the quantitation of oxycodone, noroxycodone, 6α-oxycodol, 6β-oxycodol, oxymorphone, and noroxymorphone in human blood. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1171, 122625.	1.2	1
16	Oxycodone findings and CYP2D6 function in postmortem cases. Forensic Science International: Genetics, 2021, 53, 102510.	1.6	4
17	Technical in-depth comparison of two massive parallel DNA-sequencing methods for formalin-fixed paraffin-embedded tissue from victims of sudden cardiac death. Forensic Science International: Genetics, 2021, 53, 102522.	1.6	2
18	Characteristics of post-mortem beta-hydroxybutyrate-positivet cases – A retrospective study on age, sex and BMI in 1407 forensic autopsies. Forensic Science International, 2021, 325, 110878.	1.3	3

#	Article	IF	Citations
19	Oxycodone Concentrations and Metabolic Ratios in Femoral Blood from Fatal Intoxications and Other Causes of Death using LCâ€"MS-MS. Journal of Analytical Toxicology, 2021, 45, 124-133.	1.7	5
20	JMJD1C knockdown affects myeloid cell lines proliferation, viability, and gemcitabine/carboplatin-sensitivity. Pharmacogenetics and Genomics, 2021, 31, 60-67.	0.7	5
21	Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer. World Journal of Clinical Oncology, 2021, 12, 1009-1022.	0.9	4
22	Urinary Pharmacokinetics of Immediate and Controlled Release Oxycodone and its Phase I and II Metabolites Using LCâ€"MS-MS. Journal of Analytical Toxicology, 2021, , .	1.7	0
23	Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia. Pharmacogenomics Journal, 2020, 20, 179-191.	0.9	7
24	ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide. Pharmacogenomics Journal, 2020, 20, 213-219.	0.9	9
25	Metabolism of the benzodiazepines norflurazepam, flurazepam, fludiazepam and cinolazepam by human hepatocytes using high-resolution mass spectrometry and distinguishing their intake in authentic urine samples. Forensic Toxicology, 2020, 38, 79-94.	1.4	6
26	5Fâ€'MDMBâ€'PICA metabolite identification and cannabinoid receptor activity. Drug Testing and Analysis, 2020, 12, 127-135.	1.6	41
27	Biotransformation of the New Synthetic Cannabinoid with an Alkene, MDMB-4en-PINACA, by Human Hepatocytes, Human Liver Microsomes, and Human Urine and Blood. AAPS Journal, 2020, 22, 13.	2.2	25
28	Metabolite Profiling of Ortho-, Meta- and Para-Fluorofentanyl by Hepatocytes and High-Resolution Mass Spectrometry. Journal of Analytical Toxicology, 2020, 44, 140-148.	1.7	10
29	Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel. BMC Cancer, 2020, 20, 950.	1.1	10
30	In vitro characterization of new psychoactive substances at the Î¼-opioid, CB1, 5HT1A, and 5-HT2A receptorsâ€"On-target receptor potency and efficacy, and off-target effects. Forensic Science International, 2020, 317, 110553.	1.3	10
31	Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing. Lung Cancer, 2020, 147, 106-114.	0.9	5
32	Whole-genome sequencing and gene network modules predict gemcitabine/carboplatin-induced myelosuppression in non-small cell lung cancer patients. Npj Systems Biology and Applications, 2020, 6, 25.	1.4	9
33	Hereditary Hypertrophic Cardiomyopathy in Children and Young Adultsâ€"The Value of Reevaluating and Expanding Gene Panel Analyses. Genes, 2020, 11, 1472.	1.0	9
34	Single-Cell RNA Sequencing of Hematopoietic Stem and Progenitor Cells Treated with Gemcitabine and Carboplatin. Genes, 2020, 11, 549.	1.0	2
35	The influence of ABCG2 polymorphism on erlotinib efflux in the K562 cell line. Pharmacology Research and Perspectives, 2020, 8, e00581.	1.1	3
36	Metabolism of MMB022 and identification of dihydrodiol formation in vitro using synthesized standards. Drug Testing and Analysis, 2020, 12, 1432-1441.	1.6	12

#	Article	IF	Citations
37	Whole-genome sequencing of human remains to enable genealogy DNA database searches â€" A case report. Forensic Science International: Genetics, 2020, 46, 102233.	1.6	38
38	Monozygotic twins with myocarditis and a novel likely pathogenic desmoplakin gene variant. ESC Heart Failure, 2020, 7, 1210-1216.	1.4	17
39	LC-QTOF-MS Identification of Major Urinary Cyclopropylfentanyl Metabolites Using Synthesized Standards. Journal of Analytical Toxicology, 2019, 43, 607-614.	1.7	14
40	The congenital disorder of glycosylation in PGM1 (PGM1-CDG) can cause severe cardiomyopathy and unexpected sudden cardiac death in childhood. Forensic Science International: Genetics, 2019, 43, 102111.	1.6	12
41	Erlotinib treatment induces cytochrome P450 3A activity in nonâ€small cell lung cancer patients. British Journal of Clinical Pharmacology, 2019, 85, 1704-1709.	1.1	8
42	The use of FTA cards to acquire DNA profiles from postmortem cases. International Journal of Legal Medicine, 2019, 133, 1651-1657.	1.2	12
43	Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. BMC Cancer, 2019, 19, 40.	1.1	53
44	Correlations between metabolism and structural elements of the alicyclic fentanyl analogs cyclopropyl fentanyl, cyclobutyl fentanyl, cyclopentyl fentanyl, cyclohexyl fentanyl and 2,2,3,3-tetramethylcyclopropyl fentanyl studied by human hepatocytes and LC-QTOF-MS. Archives of Toxicology, 2019, 93, 95-106.	1.9	24
45	Validation and Cross-Reactivity Data for Fentanyl Analogs With the Immunalysis Fentanyl ELISA. Journal of Analytical Toxicology, 2019, 43, 18-24.	1.7	25
46	<i><scp>ABCB</scp>1</i> Variation Affects Myelosuppression, Progressionâ€free Survival and Overall Survival in Paclitaxel/Carboplatinâ€treated Ovarian Cancer Patients. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 277-287.	1.2	10
47	Metabolism study for CUMYLâ€4CNâ€BINACA in human hepatocytes and authentic urine specimens: Free cyanide is formed during the main metabolic pathway. Drug Testing and Analysis, 2018, 10, 1270-1279.	1.6	14
48	Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial. Cancer Chemotherapy and Pharmacology, 2018, 81, 183-193.	1.1	16
49	Synthesis and identifications of potential metabolites as biomarkers of the synthetic cannabinoid AKB-48. Tetrahedron, 2018, 74, 2905-2913.	1.0	11
50	A reassessment of DNA-immunoprecipitation-based genomic profiling. Nature Methods, 2018, 15, 499-504.	9.0	92
51	Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of <i>CYP2D6</i>,<i> CYP2B6</i>, and <i>CYP3A4</i> genotype. Pharmacology Research and Perspectives, 2018, 6, e00419.	1.1	16
52	Fatal Poisonings Associated with New Psychoactive Substances. Handbook of Experimental Pharmacology, 2018, 252, 495-541.	0.9	40
53	Identifying Metabolites of Meclonazepam by High-Resolution Mass Spectrometry Using Human Liver Microsomes, Hepatocytes, a Mouse Model, and Authentic Urine Samples. AAPS Journal, 2017, 19, 736-742.	2.2	30
54	Synthesis and identification of an important metabolite of AKB-48 with a secondary hydroxyl group on the adamantyl ring. Tetrahedron Letters, 2017, 58, 1456-1458.	0.7	6

#	Article	IF	Citations
55	Simple and cost-effective liquid chromatography-mass spectrometry method to measure dabrafenib quantitatively and six metabolites semi-quantitatively in human plasma. Analytical and Bioanalytical Chemistry, 2017, 409, 3749-3756.	1.9	8
56	In Vitro and In Vivo Metabolite Identification Studies for the New Synthetic Opioids Acetylfentanyl, Acrylfentanyl, Furanylfentanyl, and 4-Fluoro-Isobutyrylfentanyl. AAPS Journal, 2017, 19, 1102-1122.	2.2	76
57	Assessing the GeneRead SNP panel for analysis of low-template and PCR-inhibitory samples. Forensic Science International: Genetics Supplement Series, 2017, 6, e267-e269.	0.1	3
58	Looking at flubromazolam metabolism from four different angles: Metabolite profiling in human liver microsomes, human hepatocytes, mice and authentic human urine samples with liquid chromatography high-resolution mass spectrometry. Forensic Science International, 2017, 274, 55-63.	1.3	28
59	Targeted Sequencing Reveals Low-Frequency Variants in <i>EPHA</i> Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy. Clinical Cancer Research, 2017, 23, 1227-1235.	3.2	16
60	Abstract 5026: Association to drug-induced leukopenia using whole-exome sequencing of non-small cell lung cancer patients on gemcitabine/carboplatin regimen. , 2017, , .		0
61	Abstract 5030: The impact ofABCB1single nucleotide polymorphisms on the outcome in lenalidomide treated multiple myeloma patients. , 2017, , .		0
62	Abstract 5028: Whole exome sequencing and genetic association of gemcitabine/carboplatin induced thrombocytopenia in non-small cell lung cancer patients. , 2017, , .		0
63	In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia. Therapeutic Drug Monitoring, 2016, 38, 230-238.	1.0	11
64	Identification of ABâ€FUBINACA metabolites in authentic urine samples suitable as urinary markers of drug intake using liquid chromatography quadrupole tandem time of flight mass spectrometry. Drug Testing and Analysis, 2016, 8, 950-956.	1.6	40
65	Determination of loss of consciousness. European Journal of Anaesthesiology, 2016, 33, 922-928.	0.7	9
66	Novel rapid liquid chromatography tandem massspectrometry method for vemurafenib and metabolites in human plasma, including metabolite concentrations at steady state. Biomedical Chromatography, 2016, 30, 1234-1239.	0.8	6
67	Putting Designer Drugs Back in Pandora's Box: Analytical Challenges and Metabolite Identification. Clinical Chemistry, 2016, 62, 4-5.	1.5	4
68	Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities. Clinical Cancer Research, 2016, 22, 366-373.	3.2	20
69	MTR-09ABCB1 AS PREDICTIVE MARKER FOR POOR SURVIVAL IN PATIENTS WITH GLIOBLASTOMA TREATED WITH RADIOTHERAPY AND CONCOMITANT AND ADJUVANT TEMOZOLOMIDE. Neuro-Oncology, 2015, 17, v126.1-v126.	0.6	2
70	Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxelâ€"Letter. Clinical Cancer Research, 2015, 21, 3092-3093.	3.2	9
71	A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2015, 107, 186-195.	1.4	25
72	Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenomics Journal, 2015, 15, 372-379.	0.9	74

#	ARTICLE	IF	CITATIONS
73	Identification of AKB-48 and 5F-AKB-48 Metabolites in Authentic Human Urine Samples Using Human Liver Microsomes and Time of Flight Mass Spectrometry. Journal of Analytical Toxicology, 2015, 39, 426-435.	1.7	46
74	Increased *Rrm2* gene dosage reduces fragile site breakage and prolongs survival of ATR mutant mice. Genes and Development, 2015, 29, 690-695.	2.7	51
75	Role of cytochrome P450 *2C8*3* (*CYP2C8*3*) in paclitaxel metabolism and paclitaxel-induced neurotoxicity. Pharmacogenomics, 2015, 16, 929-937.	0.6	17
76	*TP53* mutations and *MDM2*SNP309 identify subgroups of AML patients with impaired outcome. European Journal of Haematology, 2015, 94, 355-362.	1.1	13
77	Assessment of HaloPlex Amplification for Sequence Capture and Massively Parallel Sequencing of Arrhythmogenic Right Ventricular Cardiomyopathyâ€"Associated Genes. Journal of Molecular Diagnostics, 2015, 17, 31-42.	1.2	19
78	Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases. Pharmacogenomics Journal, 2015, 15, 165-171.	0.9	24
79	Impact of *ABCB1* single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in *FLT3* wildâ€type *de novo* AML patients with normal karyotype. British Journal of Haematology, 2014, 167, 671-680.	1.2	13
80	Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105Câ€°>â€°T have a prognostic value in acute myeloid leukemia. Biomarker Research, 2014, 2, 18.	2.8	36
81	Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line. Pharmacogenetics and Genomics, 2014, 24, 52-61.	0.7	34
82	Pharmacogenetics, Plasma Concentrations, Clinical Signs and EEG During Propofol Treatment. Basic and Clinical Pharmacology and Toxicology, 2014, 115, 565-570.	1.2	43
83	Assessment of Whole Genome Amplification for Sequence Capture and Massively Parallel Sequencing. PLoS ONE, 2014, 9, e84785.	1.1	10
84	Abstract 3518: TP53 mutations and MDM2 single nucleotide polymorphism 309T-G predicts outcome and treatment resistance in acute myeloid leukemia. , 2014, , .		0
85	Effects of nicotine, its metabolites and tobacco extracts on human platelet function in vitro. Toxicology in Vitro, 2013, 27, 932-938.	1.1	20
86	ABCB1 gene polymorphisms are associated with fatal intoxications involving venlafaxine but not citalopram. International Journal of Legal Medicine, 2013, 127, 579-586.	1.2	18
87	ABCB1 gene polymorphisms are associated with suicide in forensic autopsies. Pharmacogenetics and Genomics, 2013, 23, 463-469.	0.7	13
88	Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. Journal of Medical Genetics, 2013, 50, 599-605.	1.5	67
89	Decreased survival in normal karyotype AML with singleâ€nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5â€²â€nucleotidase. American Journal of Hematology, 2013, 88, 1001-1006.	2.0	28
90	GWAS-based association between *RWDD3* and *TECTA* variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients. Acta OncolÃ³gica, 2013, 52, 871-873.	0.8	24

#	Article	IF	Citations
91	ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro. Pharmacogenomics and Personalized Medicine, 2013, 6, 63.	0.4	18
92	Histone (H1) Phosphorylation. , 2013, , 155-189.		0
93	Abstract 1170: Correlation between cytidine deaminase single nucleotide polymorphisms andin vitrodrug sensitivity, DNA methylation and outcome in normal karyotype acute myelogenous leukemia.. , 2013, , .		0
94	IDH1 and IDH2 Mutations Are Frequent Genetic Alterations In Cytogenetically Normal Acute Myeloid Leukemia With Adverse Outcome. Blood, 2013, 122, 3894-3894.	0.6	0
95	Expression Patterns of 17Î²-Hydroxysteroid Dehydrogenase 14 in Human Tissues. Hormone and Metabolic Research, 2012, 44, 949-956.	0.7	21
96	Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype. Pharmacogenomics Journal, 2012, 12, 111-118.	0.9	38
97	Regulatory Polymorphisms in Î²-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy. Clinical Cancer Research, 2012, 18, 4441-4448.	3.2	61
98	Validation of whole genome amplification for analysis of the p53 tumor suppressor gene in limited amounts of tumor samples. Biochemical and Biophysical Research Communications, 2012, 425, 379-383.	1.0	2
99	Identification of candidate SNPs for drug induced toxicity from differentially expressed genes in associated tissues. Gene, 2012, 506, 62-68.	1.0	15
100	Semi-physiologically based pharmacokinetic modeling of paclitaxel metabolism and in silico-based study of the dynamic sensitivities in pathway kinetics. European Journal of Pharmaceutical Sciences, 2012, 47, 759-767.	1.9	3
101	Impact of <i>ABCB1</i> Variants on Neutrophil Depression: A Pharmacogenomic Study of Paclitaxel in 92 Women with Ovarian Cancer. Basic and Clinical Pharmacology and Toxicology, 2012, 110, 199-204.	1.2	36
102	Association of CYP2B6 Genotype with Survival and Progression Free Survival in Cyclophosphamide Treated Multiple Myeloma. Journal of Cancer Therapy, 2012, 03, 20-27.	0.1	5
103	Abstract 814: P-glycoprotein transport of the active imatinib metabolite, CGP74588, in chronic myeloid leukemia cells. , 2012, , .		0
104	Abstract 5596: Altered efficacy of tyrosine kinase inhibitors in chronic myeloid leukemia cells expressing wild type or polymorphic ABCG2. , 2012, , .		0
105	Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics Journal, 2011, 11, 113-120.	0.9	81
106	Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: Novel treatment predictive factors identified. Cancer Letters, 2011, 313, 145-153.	3.2	18
107	The pan-ErbB tyrosine kinase inhibitor canertinib induces caspase-mediated cell death in human T-cell leukemia (Jurkat) cells. Biochemical and Biophysical Research Communications, 2011, 410, 422-427.	1.0	8
108	The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo. Biochemical and Biophysical Research Communications, 2011, 414, 563-568.	1.0	19

#	ARTICLE	IF	CITATIONS
109	Irreversible panâ€ŁRBB inhibitor canertinib elicits antiâ€Łeukaemic effects and induces the regression of FLT3â€ŁTD transformed cells in mice. British Journal of Haematology, 2011, 155, 198-208.	1.2	7
110	Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. European Journal of Clinical Pharmacology, 2011, 67, 693-700.	0.8	70
111	Histone H1 interphase phosphorylation becomes largely established in G1 or early S phase and differs in G1 between T-lymphoblastoid cells and normal T cells. Epigenetics and Chromatin, 2011, 4, 15.	1.8	14
112	Impact of CYP3A5*3 and CYP2C8-HapC on Paclitaxel/Carboplatin-Induced Myelosuppression in Patients with Ovarian Cancer. Journal of Pharmaceutical Sciences, 2011, 100, 4205-4209.	1.6	24
113	Microtubule-targeting drugs and personalization of cancer treatment. Pharmacogenomics, 2011, 12, 449-451.	0.6	0
114	Influence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Model. Drug Metabolism and Disposition, 2011, 39, 247-255.	1.7	32
115	The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenetics and Genomics, 2011, 21, 837-850.	0.7	216
116	Functional Characterization of ABCG2 Polymorphisms and Their Influence on Tyrosine Kinase Inhibitor Effects in Chronic Myeloid Leukemia Cells,. Blood, 2011, 118, 3495-3495.	0.6	1
117	CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity. European Journal of Clinical Pharmacology, 2010, 66, 383-386.	0.8	41
118	A validated and rapid high-performance liquid chromatography method for the quantification of conversion of radio-labelled sex steroids. Hormone Molecular Biology and Clinical Investigation, 2010, 3, 375-81.	0.3	0
119	Abstract 2757: NT5C2 single nucleotide polymorphisms affects survival and response inde novoAML patients with normal karyotype. , 2010, , .		0
120	Pharmacogenetic Studies of Paclitaxel in the Treatment of Ovarian Cancer. Basic and Clinical Pharmacology and Toxicology, 2009, 104, 130-137.	1.2	111
121	Implications On Drug Resistance and Survival of ABCB1 Single Nucleotide Polymorphisms in Normal Karyotype De Novo AML.. Blood, 2009, 114, 2648-2648.	0.6	0
122	ABCB1 G1199A Polymorphism and Ovarian Cancer Response to Paclitaxel. Journal of Pharmaceutical Sciences, 2008, 97, 2045-2048.	1.6	44
123	Comparison of two types of population pharmacokinetic model structures of paclitaxel. European Journal of Pharmaceutical Sciences, 2008, 33, 128-137.	1.9	5
124	Pharmacogenomics of importance for paclitaxel chemotherapy. Pharmacogenomics, 2008, 9, 671-674.	0.6	14
125	Î²-Tubulin mutations in ovarian cancer using single strand conformation analysis-risk of false positive results from paraffin embedded tissues. Cancer Letters, 2006, 236, 148-154.	3.2	9
126	Measurement of paclitaxel and its metabolites in human plasma using liquid chromatography/ion trap mass spectrometry with a sonic spray ionization interface. Rapid Communications in Mass Spectrometry, 2006, 20, 2183-2189.	0.7	28

#	Article	IF	Citations
127	mdr-1 Single Nucleotide Polymorphisms in Ovarian Cancer Tissue: G2677T/A Correlates with Response to Paclitaxel Chemotherapy. Clinical Cancer Research, 2006, 12, 854-859.	3.2	150
128	Melanin Inhibits Cytotoxic Effects of Doxorubicin and Daunorubicin in MOLT 4 Cells. Pigment Cell & Melanoma Research, 2003, 16, 351-354.	4.0	20
129	Spontaneous Reversal of P-Glycoprotein Expression in Multidrug Resistant Cell Lines*. Basic and Clinical Pharmacology and Toxicology, 2003, 93, 297-304.	0.0	10
130	An improved procedure for the synthesis of fourteen 4-OH and 3-MeO-4OH metabolites of fentanyl analogues from two intermediates on multi-gram scale. Synthetic Communications, 0, , 1-10.	1.1	0